Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bräu N[au]:

Search results

Items: 1 to 50 of 67

1.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.

Fuchs M, Monto A, Bräu N, Charafeddine M, Schmidt W, Kozal M, Naggie S, Cheung R, Schnell G, Yu Y, Richards K, Mullally V, Cohen DE, Toro D.

J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655. [Epub ahead of print]

PMID:
31829433
2.

HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re VL.

J Natl Cancer Inst. 2019 Nov 5. pii: djz214. doi: 10.1093/jnci/djz214. [Epub ahead of print]

PMID:
31687755
3.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma.

Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V  III.

Cancer Epidemiol Biomarkers Prev. 2019 Oct 1. doi: 10.1158/1055-9965.EPI-19-0503. [Epub ahead of print]

PMID:
31575557
4.

Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.

Brown A, Welzel TM, Conway B, Negro F, Bräu N, Grebely J, Puoti M, Aghemo A, Kleine H, Pugatch D, Mensa FJ, Chen YJ, Lei Y, Lawitz E, Asselah T.

Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]

PMID:
31568620
5.

Group C Streptococcus dysgalactiae subsp.equisimilis (SDSE) Endocarditis with Endogenous Endophthalmitis and Aortic Root Abscess.

Yung L, Rashid M, Bräu N.

IDCases. 2019 Feb 26;15:e00513. doi: 10.1016/j.idcr.2019.e00513. eCollection 2019. No abstract available.

6.

Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study.

Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups.

J Clin Oncol. 2019 Feb 1;37(4):296-304. doi: 10.1200/JCO.18.00885. Epub 2018 Dec 18.

7.

Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.

Weiss JJ, Prieto S, Bräu N, Dieterich DT, Marcus SM, Stivala A, Gorman JM.

Int J Psychiatry Med. 2018 Jul;53(4):256-272. doi: 10.1177/0091217417749796. Epub 2018 Jan 3.

8.

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M.

Clin Infect Dis. 2018 May 17;66(11):1742-1750. doi: 10.1093/cid/cix1106.

PMID:
29272349
9.

Editorial: a step forward in refining prognostication for patients with HIV-associated hepatocellular carcinoma-Authors' reply.

Pinato DJ, Bräu N, Bower M.

Aliment Pharmacol Ther. 2018 Jan;47(1):134-135. doi: 10.1111/apt.14394. No abstract available.

10.

The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.

Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group.

Aliment Pharmacol Ther. 2018 Jan;47(1):95-103. doi: 10.1111/apt.14356. Epub 2017 Oct 16.

11.

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ.

N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.

12.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR.

Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.

PMID:
28390869
13.

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators.

Clin Infect Dis. 2017 Jul 1;65(1):6-12. doi: 10.1093/cid/cix260.

14.

Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.

Miller TR, Weiss JJ, Bräu N, Dieterich DT, Stivala A, Rivera-Mindt M.

J Neurovirol. 2017 Apr;23(2):260-272. doi: 10.1007/s13365-016-0494-8. Epub 2016 Nov 28.

15.

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S.

Clin Infect Dis. 2016 Oct 15;63(8):1042-1048. doi: 10.1093/cid/ciw496. Epub 2016 Jul 20.

16.

Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Cozen ML, Ryan JC, Shen H, Cheung R, Kaplan DE, Pocha C, Brau N, Aytaman A, Schmidt WN, Pedrosa M, Anand BS, Chang KM, Morgan T, Monto A.

Dig Dis Sci. 2016 Jun;61(6):1744-56. doi: 10.1007/s10620-016-4122-5. Epub 2016 Apr 8.

17.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.

18.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators.

N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

19.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group.

JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.

PMID:
25942723
20.

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.

Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford AL, Asch SM, Groessl EJ.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):2005-14.e1-3. doi: 10.1016/j.cgh.2015.02.022. Epub 2015 Feb 24.

PMID:
25724704
21.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
22.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

23.

Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS.

Clin Infect Dis. 2014 Apr;58(7):960-9. doi: 10.1093/cid/ciu009. Epub 2014 Jan 6.

24.

Impact of hepatitis C treatment initiation on adherence to concomitant medications.

Pizzirusso M, Lin J, Head C, Marcus SM, Ahmed S, Bräu N, Weiss JJ.

J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):23-31. doi: 10.1016/j.jana.2013.07.004. Epub 2013 Sep 24.

25.

Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial.

Groessl EJ, Sklar M, Cheung RC, Bräu N, Ho SB.

Contemp Clin Trials. 2013 Jul;35(2):97-107. doi: 10.1016/j.cct.2013.05.002. Epub 2013 May 10.

PMID:
23669414
26.

Evaluation of the hepatitis C virus-infected patient: the initial encounter.

Bräu N.

Clin Infect Dis. 2013 Mar;56(6):853-60. doi: 10.1093/cid/cis957. Epub 2012 Dec 12. Review.

PMID:
23243172
27.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S.

Lancet Infect Dis. 2012 Sep;12(9):671-7. doi: 10.1016/S1473-3099(12)70138-X. Epub 2012 Jun 18.

PMID:
22714001
28.

Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.

J Pharm Pract. 2012 Oct;25(5):552-9. Epub 2012 May 2.

PMID:
22551561
29.

FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients.

Park LS, Tate JP, Justice AC, Lo Re V 3rd, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2512-7. doi: 10.1158/1055-9965.EPI-11-0582. Epub 2011 Oct 25.

30.

Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.

Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Bräu N, Sterling RK, Slim J, Talal AH, Dieterich DT, Sulkowski MS.

J Hepatol. 2011 Jan;54(1):41-7. doi: 10.1016/j.jhep.2010.06.025. Epub 2010 Aug 21.

31.

In memoriam: Edmund J. Bini, MD, MPH (1967-2010).

Bräu N.

Dig Dis Sci. 2010 May;55(5):1193. doi: 10.1007/s10620-010-1224-3. No abstract available.

PMID:
20383583
32.

Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D.

Aliment Pharmacol Ther. 2009 Jul;30(1):14-27. doi: 10.1111/j.1365-2036.2009.04004.x. Epub 2009 Mar 26. Review.

33.

Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study.

Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL; VA HCV-001 Study Group.

Dig Dis Sci. 2008 Mar;53(3):809-14. Epub 2007 Sep 1.

PMID:
17823868
34.

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.

Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ; North American Liver Cancer in HIV Study Group.

J Hepatol. 2007 Oct;47(4):527-37. Epub 2007 Jul 19.

PMID:
17692986
35.

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.

Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, Tural C, Clumeck N, Nelson MR, Mendes-Correa MC, Godofsky EW, Dieterich DT, Yetzer E, Lissen E, Cooper DA.

AIDS. 2007 Jul 31;21(12):1555-9.

PMID:
17630550
36.

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.

Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, Hatzakis A, Pol S, Rockstroh J.

AIDS. 2007 May 31;21(9):1073-89. Review. No abstract available.

PMID:
17502718
37.

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?

Rodríguez-Torres M, Gonzalez-Garcia J, Bräu N, Solá R, Moreno S, Rockstroh J, Smaill F, Mendes-Correa MC, DePamphilis J, Torriani FJ; APRICOT Investigators.

J Med Virol. 2007 Jun;79(6):694-700.

PMID:
17457912
38.

Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?

Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, Jeffers L, Wright TL; VA HCV-001 Study Group.

J Clin Gastroenterol. 2007 Feb;41(2):199-205.

PMID:
17245220
39.

Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.

Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN, Jeffers L, Wright TL; VA HCV-001 Study Group.

Dig Dis Sci. 2007 Feb;52(2):570-8. Epub 2007 Jan 17.

PMID:
17226072
40.

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.

Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS.

J Viral Hepat. 2006 Oct;13(10):683-9.

PMID:
16970600
41.

National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection.

Bini EJ, Currie SL, Shen H, Bräu N, Schmidt W, Anand BS, Cheung R, Wright TL; VA HCV-001 Study Group.

J Clin Gastroenterol. 2006 Sep;40(8):732-9.

PMID:
16940888
42.

Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C.

Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N.

J Viral Hepat. 2006 Sep;13(9):613-7.

PMID:
16907848
43.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K.

J Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9.

PMID:
16765638
44.

Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender.

Rodríguez-Torres M, Ríos-Bedoya CF, Rodríguez-Orengo J, Fernández-Carbia A, Marxuach-Cuétara AM, López-Torres A, Salgado-Mercado R, Bräu N.

J Clin Gastroenterol. 2006 Apr;40(4):358-66.

PMID:
16633110
45.

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

Bräu N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, Cheung RC, Hu KQ, Anand BS, Simon FR, Aytaman A, Johnson DP, Awad JA, Ahmad J, Mendenhall CL, Pedrosa MC, Moseley RH, Hagedorn CH, Waters B, Chang KM, Morgan TR, Rossi SJ, Jeffers LJ, Wright TL; VA-HCV-001 Study Group.

J Viral Hepat. 2006 Apr;13(4):242-9.

PMID:
16611190
47.

Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.

Bräu N.

J Antimicrob Chemother. 2005 Dec;56(6):991-5. Epub 2005 Nov 24.

PMID:
16308419
48.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
49.

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M.

J Hepatol. 2006 Jan;44(1):47-55. Epub 2005 Jul 27.

PMID:
16182404
50.

Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes.

Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Bräu N, Wright TL; VA HCV-001 Study Group.

Am J Gastroenterol. 2005 Oct;100(10):2186-93.

PMID:
16181367

Supplemental Content

Support Center